Skip to main content
Premium Trial:

Request an Annual Quote

Althea Wins $100K SBIR Grant to Develop Assays for Pediatric Cancers

NEW YORK, Oct. 19 (GenomeWeb News) - Althea Technologies has received a $100,000 Phase I SBIR grant from the National Cancer Institute to help develop validated, quantitative gene-expression assays for multiple pediatric cancers.


The assays are being translated and validated to high-throughput assays using Althea's eXpress Profiling technology. The platform is a high-throughput PCR-based gene-expression analysis technique that can be used to quantitate the gene expression values of 20-35 genes in a single PCR reaction.


Serving as the basis for the development of the multiplexed PCR assays will be research performed by Javed Khan, an oncologist at the Pediatric Oncology Branch of the NCI.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.